Maliderma and Botaneco Announce Nationwide Launch of Dermylex®
Feb 16, 2012, 09:00 ET
Several National Retail Chains to Carry Product
QUEBEC CITY, Feb. 16, 2012 /CNW/ - Botaneco Corp. ("Botaneco" or the "Corporation") (TSXV: BOT), and its distributor, Maliderma Inc., are pleased to announce today the recent successful launch of Dermylex®, a natural treatment for Psoriasis, in a number of National Canadian Retail Chains. The product is commercialized under the Maliderma Dermylex® trademark and can be found in Zellers nationally excluding Quebec, Loblaw's Pharmacy select stores, Real Canadian Superstore, Atlantic Superstore and Fortinos.
Dermylex® is a protein complex derived from dairy which naturally improves the symptoms of mild to moderate Psoriasis, the most common form of the disease. Approved by Health Canada in March 2009, Dermylex® was issued a Natural Product Number (NPN) due to its solid safety and efficacy profile. Dermylex® was shown in 3 clinical studies to improve the symptoms of patients suffering from Psoriasis.
Psoriasis is a $3.4 billion market expected to double to $6.8 billion by 2019. There are multiple drugs, many with unwanted side effects, used to treat this skin disorder. Although doctors choose treatments based on the type and severity of the disease, the traditional approach is to start with the mildest treatments then progress to stronger ones only if necessary. As a nutraceutical, Dermylex® represents a safer first line treatment for the most common forms of Psoriasis.
"We are very pleased to collaborate with Maliderma in their Canadian retail launch of Dermylex®" stated Mr. Aki Georgacacos, Interim President and CEO of Botaneco. "Incorporating Dermylex® into Maliderma's consumer focused product line that includes topical applications opens further global opportunities for both companies in the future.
"Dermylex® perfectly fits our Maliderma line of efficacious but gentle products for hair and skin care" stated Mr. John Nikolaou, President of Maliderma. "We see a bright future for this product which was proven to be efficacious in several clinical studies. We intend to introduce it to other well known Canadian retailers and even through our international network of distribution partners."
Maliderma has developed a dedicated website and promotional campaign to highlight the benefits of the use of Dermylex®. Please visit www.maliderma.com/supplements.html for more details.
About Botaneco Corp.
Botaneco Corp. specializes in personal care, food and nutraceutical ingredients. We are committed to developing groundbreaking ingredients based on our patented technologies, and offering multifunctional, tangible and documented benefits to formulators and consumers alike. Botaneco is a global developer and marketer of innovative technologies that help manufacturers meet the consumers growing demand for natural, environmentally friendly, personal healthcare products. A competitive advantage to Botaneco's patented technology over traditional products in the 'green sector' is the ability to significantly enhance the performance and versatility of these skin and hair care products. The Company has also been awarded the Canadian Agri-Food Award of Excellence for its flaxseed technology marketed in the natural food industry. Botaneco holds patents for its Hydresia® Oleosome, Vegetable Oil Gel, Dermylex® Whey Protein and Flaxseed Dehulling technology.
About Maliderma Inc
Maliderma specializes in providing cutting edge, best in category, beauty and hair care products that have the distinct advantage of incorporating natural actives. All of their designed launch products provide solutions to problems for which there are little alternatives free of side effects. Maliderma works with top specialists in their fields, with the core objective to identify a focused and select group of products that would resolve common problems and ailments in a simple, quick, effective way without any side effects.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
For further information:
Chief Financial Officer
Kevin Richardson, PhD
Share this article